Prevalence and Predictors of Anticholinergic Agents in Elderly Outpatients with Dementia

Rituparna Bhattacharya MS , Satabdi Chatterjee MS , Ryan M. Carnahan PharmD, MS , Rajender R. Aparasu PhD, MPharm
{"title":"Prevalence and Predictors of Anticholinergic Agents in Elderly Outpatients with Dementia","authors":"Rituparna Bhattacharya MS ,&nbsp;Satabdi Chatterjee MS ,&nbsp;Ryan M. Carnahan PharmD, MS ,&nbsp;Rajender R. Aparasu PhD, MPharm","doi":"10.1016/j.amjopharm.2011.10.001","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><p>Anticholinergic medications, although frequently used in elderly populations, are associated with cognitive impairment and constitute significant concern for patients with dementia.</p></div><div><h3>Objective</h3><p>The purpose of our study was to examine patterns and predictors of prescribing anticholinergic agents for elderly outpatients with dementia.</p></div><div><h3>Methods</h3><p>We combined data from the 2006–2007 National Ambulatory Medical Care Survey and the outpatient department component of National Hospital Ambulatory Medical Care Survey to analyze patient visits by elderly persons (aged ≥65 years) with dementia. Anticholinergic drugs were identified using the Anticholinergic Drug Scale, which classifies anticholinergic drugs into four levels (0–3) in increasing order of anticholinergic activity. Descriptive analysis using sampling weights was used to evaluate patterns of anticholinergic drug prescription, especially prescribing of medications with clinically significant anticholinergic activity (ie, levels 2 or 3). Multiple logistic regression was used in the conceptual framework of the Andersen Behavioral Model to examine the predisposing, enabling, and need factors associated with prescribing of medications with clinically significant anticholinergic activity.</p></div><div><h3>Results</h3><p>According to the national surveys there were a total of 6.8 million (95% CI, 5.27–8.44 million; 0.32%) ambulatory care visits for dementia. Approximately 43% (42.86%; 95% CI, 35.24–50.48) of these visits involved prescribing at least one anticholinergic drug; and 10.07% of visits involved prescribing levels 2 or 3 anticholinergic medications. The predisposing factor, age (75–84 years; odds ratio [OR] = 0.25; 95% CI, 0.07–0.87), and the need factors, acetylcholinesterase inhibitor use (OR = 0.25; 95% CI, 0.07–0.86) and comorbid mood disorders (OR = 0.12; 95% CI, 0.02–0.73), were associated with decreased likelihood of prescribing medications with clinically significant anticholinergic activity. The need factor total number of medications prescribed (OR = 1.45, 95% CI, 1.20–1.75) increased the likelihood of these prescriptions being administered.</p></div><div><h3>Conclusions</h3><p>One in 10 outpatient visits by elderly persons with dementia involved prescribing medications with clinically significant anticholinergic activity. Given their adverse cognitive effects, there is a strong need to optimize anticholinergic drug prescribing in vulnerable elderly outpatients with dementia.</p></div>","PeriodicalId":50811,"journal":{"name":"American Journal Geriatric Pharmacotherapy","volume":"9 6","pages":"Pages 434-441"},"PeriodicalIF":0.0000,"publicationDate":"2011-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.amjopharm.2011.10.001","citationCount":"41","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"American Journal Geriatric Pharmacotherapy","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1543594611001723","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 41

Abstract

Background

Anticholinergic medications, although frequently used in elderly populations, are associated with cognitive impairment and constitute significant concern for patients with dementia.

Objective

The purpose of our study was to examine patterns and predictors of prescribing anticholinergic agents for elderly outpatients with dementia.

Methods

We combined data from the 2006–2007 National Ambulatory Medical Care Survey and the outpatient department component of National Hospital Ambulatory Medical Care Survey to analyze patient visits by elderly persons (aged ≥65 years) with dementia. Anticholinergic drugs were identified using the Anticholinergic Drug Scale, which classifies anticholinergic drugs into four levels (0–3) in increasing order of anticholinergic activity. Descriptive analysis using sampling weights was used to evaluate patterns of anticholinergic drug prescription, especially prescribing of medications with clinically significant anticholinergic activity (ie, levels 2 or 3). Multiple logistic regression was used in the conceptual framework of the Andersen Behavioral Model to examine the predisposing, enabling, and need factors associated with prescribing of medications with clinically significant anticholinergic activity.

Results

According to the national surveys there were a total of 6.8 million (95% CI, 5.27–8.44 million; 0.32%) ambulatory care visits for dementia. Approximately 43% (42.86%; 95% CI, 35.24–50.48) of these visits involved prescribing at least one anticholinergic drug; and 10.07% of visits involved prescribing levels 2 or 3 anticholinergic medications. The predisposing factor, age (75–84 years; odds ratio [OR] = 0.25; 95% CI, 0.07–0.87), and the need factors, acetylcholinesterase inhibitor use (OR = 0.25; 95% CI, 0.07–0.86) and comorbid mood disorders (OR = 0.12; 95% CI, 0.02–0.73), were associated with decreased likelihood of prescribing medications with clinically significant anticholinergic activity. The need factor total number of medications prescribed (OR = 1.45, 95% CI, 1.20–1.75) increased the likelihood of these prescriptions being administered.

Conclusions

One in 10 outpatient visits by elderly persons with dementia involved prescribing medications with clinically significant anticholinergic activity. Given their adverse cognitive effects, there is a strong need to optimize anticholinergic drug prescribing in vulnerable elderly outpatients with dementia.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
老年痴呆门诊患者抗胆碱能药物的患病率及预测因素
背景:抗胆碱能药物虽然经常用于老年人群,但与认知功能障碍有关,对痴呆患者构成重大关注。目的探讨老年痴呆门诊患者使用抗胆碱能药物的模式和预测因素。方法结合2006-2007年全国门诊医疗调查和全国医院门诊医疗调查的门诊部分数据,分析老年痴呆患者(年龄≥65岁)的就诊情况。采用《抗胆碱能药物量表》对抗胆碱能药物进行鉴定,该量表将抗胆碱能药物按照抗胆碱能活性的递增顺序分为4级(0-3级)。使用抽样权重的描述性分析来评估抗胆碱能药物处方模式,特别是处方具有临床显著抗胆碱能活性的药物(即2级或3级)。在Andersen行为模型的概念框架中使用多元逻辑回归来检查与处方具有临床显著抗胆碱能活性的药物相关的易感因素、使能因素和需求因素。结果全国调查共有680万例(95% CI, 527 - 844万;0.32%)痴呆症门诊就诊。约43% (42.86%;95% CI, 35.24-50.48),这些就诊涉及处方至少一种抗胆碱能药物;10.07%的就诊涉及处方2级或3级抗胆碱能药物。易感因素:年龄(75-84岁);优势比[OR] = 0.25;95% CI, 0.07-0.87),以及需要因素,乙酰胆碱酯酶抑制剂的使用(OR = 0.25;95% CI, 0.07-0.86)和共病性情绪障碍(OR = 0.12;95% CI, 0.02-0.73),与处方具有临床显著抗胆碱能活性药物的可能性降低相关。处方药物的需求因子总数(OR = 1.45, 95% CI, 1.20-1.75)增加了这些处方被使用的可能性。结论:老年痴呆患者每10例门诊就诊中就有1例处方具有临床显著抗胆碱能活性的药物。鉴于其不利的认知影响,有强烈的需要优化抗胆碱能药物处方易受伤害的老年痴呆门诊患者。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
American Journal Geriatric Pharmacotherapy
American Journal Geriatric Pharmacotherapy GERIATRICS & GERONTOLOGY-PHARMACOLOGY & PHARMACY
自引率
0.00%
发文量
0
审稿时长
>12 weeks
期刊最新文献
Author Index Subject Index Editorial Board Adverse Effects of Analgesics Commonly Used by Older Adults With Osteoarthritis: Focus on Non-Opioid and Opioid Analgesics Effect of Combination Fluticasone Propionate and Salmeterol or Inhaled Corticosteroids on Asthma-Related Outcomes in a Medicare-Eligible Population
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1